TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years age ≤ 80 years age~* voluntarily signed informed consent~* 15 ml/min/1,73 m2 ≤ estimated Glomerular Filtration Rate \< 60 ml/min/1,73 m2~* BP ≥ 130/80 mmHg or undergoing anti-hypertensive treatment~Exclusion Criteria:~* p-potassium is \> 5.0 mM~* allergy to contents~* treated with spironolactone~* treated with potent inhibitors of CYP3A4 (see SPC for details)~* treated with lithium, ciclosporin, tacrolimus, prednisolone, or other immunosuppressing drug~* inborn errors of metabolism (see SPC for details)~* pregnancy or lactation~* fertile woman, not using safe contraception devices~* dementia or other psychiatric disorder, making understanding of the study conditions impossible~* other severe, chronic illness besides CKD, including liver insufficiency, according to investigators' judgement~* vascular surgery including stenting or graft implantation on a. brachialis, aorta or the carotid arteries~* systolic BP \> 200 mmHg~* immeasurable pulse amplitude

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with an acute total joint infection~Exclusion Criteria:~* History of alcoholism~* Unable to return for follow-up~* Refuses to participate in the study~* Does not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Collatamp sponge (Type: NO_INTERVENTION): Joint infection treated without the use of the Collatamp G sponge.
- Collatamp G sponge (Type: EXPERIMENTAL): Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multiethnic subjects~* 18 to 50 YO~* Phototype III-VI~* All skin types~* 50% with sensitive skin (declarative)~* Symmetrical mild to moderate facial post-acne PIHP lesions with IGA scale~* Mild active acne (less than 10 retention and 5 inflammatory lesions)~* Agreeing not to change their lifestyle during the study period.~* Capable of reading the documents presented to them, of adhering to the study regulations and accepting the limitations.~* Available to follow the study~* Agreeing to participate and having signed the informed consent~Exclusion Criteria:~* Moderate to severe active acne~* Patients under topical or systemic retinoids~* Patients under systemic immunosuppressants~* Patients under active treatment of PIHP (including topicals or procedures) within the last 3 months~* Patients treated with facial procedures within the last 3 months~* Pregnancy~* Patient with a recent change in contraception (since less than 6 months)~* Known allergy to any component of tested product~* Not presenting with the conditions needed to comply with the protocol.~* Unable to give their informed consent~* Not available to follow the study in its entirety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Participant will receive sunscreen in the morning and at the beginning of the afternoon for 3 months.
- Liftactiv B3 (Type: EXPERIMENTAL): Participants will undergo a wash out phase of two weeks where they regularly apply a moisturizer (Hydreane Legere) in the morning and a sunscreen in the morning and at the beginning of the afternoon. On the 3rd week, participants will apply Liftactiv B3 serum daily in the morning before sunscreen and in the evening (two applications daily) on half face for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Split Cohort Trial Comparing IVF Outcomes After the Use of Testicular vs. Ejaculated Sperm for ICSI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing to comply with all study procedures and be available for the duration of the study~* Failed at least one IVF cycle (i.e., no live birth)~* Elevated DNA fragmentation noted in ejaculated sperm (\>25% DFI according to the American Society of Reproductive Medicine guidelines)~* Couple electing single embryo transfer~* Couples electing comprehensive chromosome screening (CCS) of embryos~* At least 4 oocytes retrieved in IVF cycle in order to randomize~Exclusion Criteria:~* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.~* Contraindication to IVF~* Clinical indication for preimplantation genetic diagnosis (PGD) (i.e., screening for single gene disorder, chromosomal translocation, or any other disorders requiring detailed embryo genetic analysis)~* Male partner with azoospermia (\<100,000 motile spermatozoa)~* Male partner with Y-chromosome microdeletion~* Male partner with any Karyotype other than 46,XY(normal male karyotype)~* Female partner history of hydrosalpinges or adnexal mass~* Female partner history of endometrial insufficiency (max endometrial thickness \< 7mm)~* Female partner BMI \< 35

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Study Arms:
- elevated sperm DNA fragmentation (Type: None): Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (\>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate~* Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy~* Detectable metastases~* ECOG performance status ≤2 (Performance status of 3 if due to bone pain)~* Any Gleason score~* Only one prior treatment with systemic chemotherapy~* No prior treatment with gene therapy~* No prior immunotherapy for prostate cancer~* Taxane naïve~* Experiencing cancer-related pain

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated, apparently resectable, adenocarcinoma of the pancreas at registration.~* Age greater than or equal to 18 years~* Medically fit for surgery in the opinion of the treating surgeon~* Ability to provide written informed consent~Exclusion Criteria:~- Patients who are currently pregnant, planning to become pregnant, or breast-feeding.~Note: women of childbearing potential must agree to use a medically accepted form of birth control including (condoms, diaphragms, cervical cap, an intra-uterine device (IUD), surgical sterility \[tubal ligation or a partner that has undergone a vasectomy\], or oral contraceptives). OR must agree to completely abstain from intercourse for two weeks before beginning study treatment, during participation in this study, and for 2 weeks after the final study treatment~* Patients with hypercalcemia (blood levels greater than 11.5 mg/dL). Note: In patients with GFR 30-60 mL/min by Cockroft-Gault, blood calcium levels must be 9.5 mg/dL or lower before starting paricalcitol.~* Serum creatinine \> 2.5 x ULN OR GFR \<30 mL/min by Cockroft-Gault formula . Patients who, in the opinion of the physician, would not be clinically appropriate for receipt of the therapy regimen associated with participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Arm A: 50mcg IV weekly
- Arm B (Type: EXPERIMENTAL): Arm B: 12mcg PO daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Breathing Intervention for Cardiac Anxiety

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 80~* BMI 17 to 35~* Proficient in English language~* Paroxysmal atrial fibrillation or ventricular fibrillation or frequent premature atrial/ventricular contractions~Exclusion Criteria:~* No telephone access~* Active suicidal ideation with intent or plan~* Active drug or alcohol dependence, or active binge drinking within the last month~* Cardiovascular instability, as evidenced any of the following:~  1. New York Heart Association (NHYA) heart failure class IV (i.e., unable to carry on any physical activity without discomfort, symptoms of heart failure at rest, increased discomfort with any physical activity is undertaken)~ 2. American College of Cardiology/American Heart Association congestive heart failure stage D (i.e., heart failure symptoms at rest, receiving end of life care).~ 3. Unstable angina or exercise induced angina~ 4. Persistent atrial fibrillation~* Pacemakers or combined pacemaker/ICDs will be excluded~* Presence of unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disease; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Breathing exercise (Type: EXPERIMENTAL): Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Effectiveness of Oral Versus Intravenous Pain Medicine for Suction Curettage (D&C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older.~* Undesired pregnancy between 6 0/7-12 6/7 weeks gestation.~* Has already signed consent for pregnancy termination.~* Eligible for IV sedation per clinic protocol.~Exclusion Criteria:~* Under 120 lbs.~* Allergies to any of the drugs being studied.~* Chronic narcotics, barbiturates or benzodiazepine use within the past year.~* History of IV drug use within the last year.~* Inability to give informed consent.~* Does not speak English or Spanish and does not have translator for all study procedures~* Previously participated in study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Myo-inositol Versus Clomiphene Citrate in PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rotterdam criteria for PCOS (cf. the recent ESHRE guidelines): at least 2 out of 3 criteria should be fulfilled: irregular cycle (shorter than 21 days or longer than 35 days); clinical (modified Ferriman-Gallwey score ≥ 6) or biochemical signs (elevated free testosterone) of hyperandrogenism (www.eshre.eu/Guidelines-and- Legal/Guidelines/Polycystic-Ovary-Syndrome.aspx); PCO ovaries on ultrasound (www.eshre.eu/Guidelines-and- Legal/Guidelines/Polycystic-Ovary-Syndrome.aspx): multiple small cysts (≥ 20 per ovary and/or an ovarian volume ≥ 10 ml, measured with a probe \>8 MHz) in both ovaries.~* A first treatment cycle, possibly combined with intra uterine insemination (IUI) and this for (one of) the following reasons: mild male factor (as defined by each local center) endometriosis AFS score 1 or 2~* Use of own or donor sperm.~Exclusion Criteria:~* Tubal factors~* Uterine factors~* Endometriosis AFS score 3 or 4~* Moderate to severe male factor (as defined by each local center)~* BMI \> 35

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Inositol group (Type: EXPERIMENTAL): Myo-inositol 4000 mg Dosing: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged) during 3 consecutive treatment cycles.
- Clomiphene citrate group (Type: ACTIVE_COMPARATOR): Each tablet contains 50 mg of clomiphene citrate Dosing: 1 tablet per day, per os, from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days during 3 consecutive treatment cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Non-hysterectomized, menopausal women between the ages of 35 and 65 years (inclusive) with symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen therapy as determined by patient report and the Investigator's clinical judgement

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* presence of a subepithelial gastric tumor with signs of potential malignancy in endoscopic ultrasound~* age 18 years or older~* participant has given informed consent~Exclusion Criteria:~* tumor size \> 40 mm (endosonographic measurement) or large extramural tumor mass~* signs of systemic dissemination of tumor~* current presence of a different neoplastic disease (except after successful curative treatment without continued medication)~* former surgery or disease of esophagus or stomach that impedes insertion of the suturing device~* moribund patient~* limited possibility to give informed consent (e.g. language barrier, psychiatric disease)~* pregnancy and lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EFTR-GERDX (Type: None): Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main inclusion criteria:~* The patient has completed the 16026A study and has received the last study treatment within 12 months of the screening visit for the present study.~* The patient has an MRI scan done in relation to study 16026A performed within 9 months before first study visit in the extension study.~* The patient has a knowledgeable and reliable caregiver/ study partner who will be available and able to accompany the patient to clinical visits, monitor Immunisation-Related Events after each immunisation, and participate with the patient at phone visits during the study~Main exclusion criteria:~* The patient uses or has recently used (pre-trial time limits specified in Appendix II) disallowed concomitant medication or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications (Appendix II) during the study.~* The patient has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety and tolerability~More inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Lu AF20513 high dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Has a residual invasive cancer in the breast(non-pCR) after neoadjuvant treatment~* Has stage I, II, or III disease prior to surgery per American Joint Committee on Cancer (AJCC)~* HER 2 1+ by IHC or HER2 2+by IHC without gene amplification by ISH, as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.~* Hormone receptor (ER and PR) negative by ASCO/CAP guidelines~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Demonstrates adequate organ function.~Key Exclusion Criteria:~* Has a history of hypersensitivity or other contraindications to rhGM-CSF~* Has a history of invasive malignancy ≤5 years prior to first administration of investigational drug except for adequately treated non-melanoma skin cancer or carcinoma in situ.~* Is on immune suppression therapy or has a history of immune suppression therapy ≤4 weeks prior to the first administration of investigational drugs~* Has a history of autoimmune disease or inflammatory disease~* Has active infection including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection~* Is pregnant or breastfeeding or expecting to conceive children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AST-301(pNGVL3-hICD)+Chemotherapy (Type: EXPERIMENTAL): * AST-301/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy\*~* A booster (AST-301/rhuGM-CSF) at 24 weeks post the third vaccination~  * Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)
- Placebo + Chemotherapy (Type: ACTIVE_COMPARATOR): * Placebo/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy\*~* A booster (Placebo/rhuGM CSF) at 24 weeks post the third vaccination~  * Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues